Labcorp to Acquire Oncology Testing Businesses of OPKO Health's BioReference Health Unit

MT Newswires Live03-11

Labcorp Holdings (LH) has agreed to acquire certain assets of OPKO Health's (OPK) BioReference Health unit for up to $225 million, the companies said Tuesday.

The purchase price includes $192.5 million payable at closing and up to $32.5 million in earnout payments based on performance, the companies said.

Under the deal, Labcorp will acquire BioReference Health's oncology-related laboratory testing businesses and clinical testing services in the US, along with certain customer accounts and other operating assets, the companies said.

The assets being acquired currently generate about $85 million to $100 million in annual revenue and Labcorp said it expects the acquisition to be accretive to earnings in the first year.

The transaction is expected to close in the second half of 2025, the companies said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2518710736?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-11 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518710736","market":"sg","top_or_hot":-1,"title":"Labcorp to Acquire Oncology Testing Businesses of OPKO Health's BioReference Health Unit","media":"MT Newswires Live","content":"<html><body><p> Labcorp Holdings (LH) has agreed to acquire certain assets of OPKO Health's (OPK) BioReference Health unit for up to $225 million, the companies said Tuesday.</p><p>The purchase price includes $192.5 million payable at closing and up to $32.5 million in earnout payments based on performance, the companies said.</p><p>Under the deal, Labcorp will acquire BioReference Health's oncology-related laboratory testing businesses and clinical testing services in the US, along with certain customer accounts and other operating assets, the companies said.</p><p>The assets being acquired currently generate about $85 million to $100 million in annual revenue and Labcorp said it expects the acquisition to be accretive to earnings in the first year.</p><p>The transaction is expected to close in the second half of 2025, the companies said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp to Acquire Oncology Testing Businesses of OPKO Health's BioReference Health Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp to Acquire Oncology Testing Businesses of OPKO Health's BioReference Health Unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-11 19:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Labcorp Holdings (LH) has agreed to acquire certain assets of OPKO Health's (OPK) BioReference Health unit for up to $225 million, the companies said Tuesday.</p><p>The purchase price includes $192.5 million payable at closing and up to $32.5 million in earnout payments based on performance, the companies said.</p><p>Under the deal, Labcorp will acquire BioReference Health's oncology-related laboratory testing businesses and clinical testing services in the US, along with certain customer accounts and other operating assets, the companies said.</p><p>The assets being acquired currently generate about $85 million to $100 million in annual revenue and Labcorp said it expects the acquisition to be accretive to earnings in the first year.</p><p>The transaction is expected to close in the second half of 2025, the companies said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2518710736","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518710736","pubTimestamp":1741693944,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Labcorp Holdings  has agreed to acquire certain assets of OPKO Health's  BioReference Health unit for up to $225 million, the companies said Tuesday.The purchase price includes $192.5 million payable at closing and up to $32.5 million in earnout payments based on performance, the companies said.Under the deal, Labcorp will acquire BioReference Health's oncology-related laboratory testing businesses and clinical testing services in the US, along with certain customer accounts and other operating assets, the companies said.The assets being acquired currently generate about $85 million to $100 million in annual revenue and Labcorp said it expects the acquisition to be accretive to earnings in the first year.The transaction is expected to close in the second half of 2025, the companies said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4550":"红杉资本持仓","BK4588":"碎股","OPK":"Opko Health","LH":"徕博科","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4196":"保健护理服务"},"translate_title":"Labcorp将收购OPKO Health生物参考健康部门的肿瘤检测业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":0.9,"OPK":1},"content_text":"Labcorp Holdings (LH) has agreed to acquire certain assets of OPKO Health's (OPK) BioReference Health unit for up to $225 million, the companies said Tuesday.The purchase price includes $192.5 million payable at closing and up to $32.5 million in earnout payments based on performance, the companies said.Under the deal, Labcorp will acquire BioReference Health's oncology-related laboratory testing businesses and clinical testing services in the US, along with certain customer accounts and other operating assets, the companies said.The assets being acquired currently generate about $85 million to $100 million in annual revenue and Labcorp said it expects the acquisition to be accretive to earnings in the first year.The transaction is expected to close in the second half of 2025, the companies said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518710736"}